⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
EVMN News
Evommune, Inc.
Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria
businesswire.com
EVMN
Form 8-K
sec.gov
EVMN
Form 8-K
sec.gov
EVMN
Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights
businesswire.com
EVMN
Form 8-K
sec.gov
EVMN
Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine
businesswire.com
EVMN
Form 8-K
sec.gov
EVMN
Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights
businesswire.com
EVMN
Evommune Announces $125 Million Private Placement
businesswire.com
EVMN
Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis
businesswire.com
EVMN